Academic Journal
Predicting Progestin Therapy Response With PTEN, PAX2, and β-Catenin in Patients With Endometrioid Precancer
| العنوان: | Predicting Progestin Therapy Response With PTEN, PAX2, and β-Catenin in Patients With Endometrioid Precancer |
|---|---|
| المؤلفون: | Liu, Naijia, Lin, Wanrun, Wang, Yan, Yao, Zhigang, Rivera-Colon, Glorimar, Li, Yan, Carrick, Kelley S., Chen, Hao, Lucas, Elena, Zheng, Wenxin |
| المصدر: | International Journal of Gynecological Pathology ; volume 43, issue 5, page 494-505 ; ISSN 0277-1691 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2024 |
| الوصف: | This study investigates the predictive value of biomarkers PTEN, PAX2, and β-catenin for therapeutic outcomes in patients with atypical endometrial hyperplasia or endometrioid intraepithelial neoplasia undergoing progestin therapy. In a retrospective study of 128 patients, we analyzed a total of 351 endometrial biopsy samples and categorized outcomes into responders (absence of residual disease) and nonresponders (presence of residual disease). We found aberrant biomarker expression in pretreatment cases: 48% for PTEN, 65% for PAX2, and 36% for β-catenin. Approximately 77.3% of patients responded to progestin treatment, with nonresponders showing significantly higher initial PTEN loss (75.86% vs 39.79%, P < 0.001). Nonresponders also demonstrated significant PTEN loss (53.33% vs 20.55%, P < 0.001), PAX2 loss (57.33% vs 41.22%, P < 0.05), and β-catenin nuclear staining (53.45% vs 27.91%, P < 0.01) in follow-up samples. In addition, nonresponders exhibited lower recovery of intact PTEN and PAX2, along with higher β-catenin aberrancy in cases initially showing normal β-catenin levels. We conclude that persistent aberrant PTEN and PAX2 expression, coupled with emerging aberrant β-catenin in follow-ups, indicates a greater likelihood of treatment failure. Conversely, the absence of these aberrations suggests successful progestin therapy. Our findings highlight the utility of this 3-marker panel in assessing residual disease status and predicting progestin treatment outcomes, thus offering critical insights for patient management. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1097/pgp.0000000000001008 |
| DOI: | 10.1097/PGP.0000000000001008 |
| الاتاحة: | https://doi.org/10.1097/pgp.0000000000001008 https://journals.lww.com/10.1097/PGP.0000000000001008 |
| رقم الانضمام: | edsbas.1D65E197 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/pgp.0000000000001008 |
|---|